Virology News: Breaking Virology News, Comments and Articles. - Page: 5

Rihanna Herpes and Lipstick Fiasco Shows Need for Effective Herpes Remedy; polyDNA Recommends Gene-Eden-VIR to Kill Latent Herpes Virus

The FDA says “Don't share or swap eye cosmetics - not even with your best friend.. The risk of contamination may be even greater with ‘testers' at retail stores.” (1) polyDNA Recommends to protect against infection with Gene-Eden-VIR. Rochester, NY (PRWEB) June 11, 2013 The National Health Service website says that “It is not possible to prevent becoming infected with the herpes s...

WHO Says MERS Coronavirus Has Pandemic Qualities

Lawrence LeBlond for redOrbit.com - Your Universe Online The World Health Organization (WHO) met with the officials from the Kingdom of Saudi Arabia (KSA) last week to discuss and assess the MERS-coronavirus outbreak that has been steadily growing in the Middle East and surrounding countries. The virus, which was recently renamed from novel coronavirus to Middle East respiratory syndrome-coronav...

Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline

EXTON, Pa., June 11, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in their TreatmentTrends®: Hepatitis C Virus (EU) report, that surveyed gastroenterologists and hepatologists in Spain and France are more likely to be aware of emerging HCV drugs than their counterparts in the United Kingdo...

Medicago “first in the world” to report positive pre-clinical data for H7N9 vaccine

Medicago has announced that it is “first in the world” to report positive interim results from a pre-clinical trial for an H7N9 Virus-Like Particle (VLP) [...]

MERS Not Spreading Widely In Saudi Arabia, Experts Believe

The MERS coronavirus does not appear to be spreading widely in Saudi Arabia, says an international team of experts who formed a Joint Mission of the World Health Organization and the Kingdom of Saudi Arabia that has just concluded a 6-day study. The...

Study shows iron-uptake receptor plays a role in HCV infection

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload.

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiat...

Medicago Receives Authorization from Health Canada and Commences Phase II Clinical Trial for an H5N1 Vaccine

QUEBEC CITY, June 11, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza...

Adult Vaccination Rates Rise, but Not Enough

Vaccines are just for kids, right? Not any more. U.S. health officials now recommend at least a half dozen vaccines for adults, to prevent pneumococcus virus, hepatitis, shingles and other ailments. And although the portion of adults who get these va...

Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx

Jiangsu Chia-tai Tianqing Pharmaceutical Co. in-licensed China rights to BL-8030, an oral treatment for hepatitis C virus, from BioLineRx, an Israeli clinical-stage pharma. CTTQ makes chemical drugs and TCM products, with liver disease a specialty fo...

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

Hepatitis C virus infection is a major cause of liver cirrhosis and cancer, and current therapies are often ineffective or have severe side effects. Here, Bartenschlager and colleagues review how structural and functional insights into the viral life...

Advanced Biological Laboratories acquires Evivar Medical

Advanced Biological Laboratories (ABL) has acquired all the assets of Evivar Medical (Evivar), which includes its Hepatitis B virus (HBV) and C (HCV) web-based decision support tools and the associated viral genome analysis systems (SeqHepB and SeqHe...

Immune Response Exploited By Herpes Virus To Bolster Infection

Researchers at the University of California, San Diego School of Medicine and colleagues report that the herpes simplex virus type-1 (HSV-1), which affects an estimated 50 to 80 percent of all American adults, exploits an immune system receptor to bo...

Hepatitis C virus entry factor identified

A new study reveals that HCV not only alters expression of the iron-uptake receptor known as transferrin receptor 1 (TfR1) but that TfR1 also mediates HCV entry.

New study on hepatitis C virus entry factor: Researchers identify disruption of iron uptake receptor

Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload. A new study completed by researchers at Loyol...

Widespread Ignorance of Medication That Prevents HIV

In Washington DC, which has one of the highest HIV rates in the world, only 10% of at-risk people know there is medication they can take to ward off the virus. Medscape Medical News

NanoViricides Submits DengueCide™ Orphan Drug Designation Application to the US FDA for Dengue and Dengue Hemorrhagic Fever

NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development (OOPD) of the US FDA for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. The Company previously engaged the consulting firm Cote´ Orphan Co...

BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics

- BL-8030 is a pre-clinical, second-generation NS3 protease inhibitor - - CTTQ receives development and commercialization rights in China and Hong Kong - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceut...

ABL Acquires Evivar Medical Assets and Further Enhances its IT Solutions and Personalized Healthcare Platform for Hepatitis B, Hepatitis C and HIV Infections

Advanced Biological Laboratories S.A (ABL) today announced the acquisition of all the assets of Evivar Medical Pty Ltd (Evivar), which includes Evivar’s Hepatitis B virus (HBV) and C (HCV) web-based decision support tools for clinicians and the associated viral genome analysis systems (SeqHepB and SeqHepC), intellectual property portfolio, and all relate...

Nutra Pharma Announces Licensing Agreement for the Marketing and Distribution of Its All-Natural Pain Reliever, Cobroxin®

CORAL SPRINGS, Fla., June 10, 2013 /PRNewswire/ -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company has entered into a licensing agreement with Cobra Pharmaceuticals for the re-launch of their all-natural, non-addictive...

CONCERTO hints at simeprevir's Japan potential

Janssen (Johnson & Johnson) has released the first detailed data from a suite of studies used to support the Japanese approval filing earlier this year for its hepatitis C virus (HCV) drug simeprevir (TMC435). The February.....

NBLCA Supports Proposed New York State Legislation That Would Expand Testing for Hepatitis C Virus in Baby Boomers

NEW YORK, June 10, 2013 /PRNewswire-USNewswire/ -- The National Black Leadership Commission on AIDS, Inc. (NBLCA) is working in partnership with allied organizations to advocate for the passage of New York State Senate (S2750) and Assembly (A1286) bills to expand access to testing for the Hepatitis C virus (HCV), which has reached epidemic proportions in New York and the United States. The pr...

Gilead gains FDA priority review for hep C candidate sofosbuvir; new data on Boehringer's faldaprevir

US biotech firm Gilead Sciences (Nasdaq: GILD) revealed on Friday (June 7) that the US Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for...

Middle East respiratory syndrome coronavirus: Joint Kingdom of Saudi Arabia/WHO mission

10 June 2013 -- Between 4 and 9 June 2013, a joint mission of the Kingdom of Saudi Arabia and the World Health Organization (WHO) met in Riyadh to assess the situation due to a new coronavirus in the Kingdom. This virus has recently been named the Middle East respiratory syndrome coronavirus (MERS-CoV). It is a new, emerging virus that is distantly related to the virus that caused SARS.

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic are...